Literature DB >> 20573405

Pro-inflammatory cytokine and chemokine mRNA blood level in multiple sclerosis is related to treatment response and interferon-beta dose.

Angele Cucci1, Pierangelo Barbero, Marinella Clerico, Bruno Ferrero, Elisabetta Versino, Giulia Contessa, Stefania Demercanti, Emanuela Viglietta, Alessandra Di Liberto, Alessandra Giai Vai, Luca Durelli.   

Abstract

Of 37 multiple sclerosis patients, 19 suboptimal responders were randomized to 375 (n=12) or 250µg (n=7) interferon (IFN)-β-1b. mRNA levels of 23 cytokines, chemokines, and chemokine receptors were quantified by TaqMan low-density array (TLDA) real-time polymerase chain reaction. Better treatment responses or increased IFN-β doses were associated with elevated IL-10 and TGF-β and decreased CXCL10, IL-18, IFN-γ, and TNF-α transcript levels. Adjusting for dose, poor treatment responses resulted in a 4-fold increase in CXCL10 and IFN-γ expression (Mantel-Haenszel RR=3.74, p<0.0001). CXCL10 and IFN-γ mRNA levels were reliable indicators of treatment response. TLDA can be used to tailor IFN-β-1b therapy.
Copyright © 2010 Elsevier B.V. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20573405     DOI: 10.1016/j.jneuroim.2010.05.038

Source DB:  PubMed          Journal:  J Neuroimmunol        ISSN: 0165-5728            Impact factor:   3.478


  10 in total

1.  Interleukin 18 gene polymorphism is a risk factor for multiple sclerosis.

Authors:  Sevim Karakas Celik; Zehra Safi Öz; Ahmet Dursun; Aysun Unal; Ufuk Emre; Salih Cicek; Fatih Mehmet Keni
Journal:  Mol Biol Rep       Date:  2014-01-09       Impact factor: 2.316

2.  EBV and vitamin D status in relapsing-remitting multiple sclerosis patients with a unique cytokine signature.

Authors:  Ahmad Nejati; Zabihollah Shoja; Shohreh Shahmahmoodi; Abbas Tafakhori; Yaghoub Mollaei-Kandelous; Farhad Rezaei; Kabir Magaji Hamid; Abbas Mirshafiey; Rozita Doosti; Mohammad Ali Sahraian; Mahmood Mahmoudi; Fazel Shokri; Vince Emery; Sayed Mahdi Marashi
Journal:  Med Microbiol Immunol       Date:  2015-09-13       Impact factor: 3.402

3.  Cytokine Profile in Patients with Progressive Multiple Sclerosis and Its Association with Disease Progression and Disability.

Authors:  Ana Paula Kallaur; Sayonara Rangel Oliveira; Andréa Name Colado Simão; Daniela Frizon Alfieri; Tamires Flauzino; Josiane Lopes; Wildea Lice de Carvalho Jennings Pereira; Caio de Meleck Proença; Sueli Donizete Borelli; Damacio Ramón Kaimen-Maciel; Michael Maes; Edna Maria Vissoci Reiche
Journal:  Mol Neurobiol       Date:  2016-03-29       Impact factor: 5.590

4.  The Effects of IFN-β 1a on the Expression of Inflammasomes and Apoptosis-Associated Speck-Like Proteins in Multiple Sclerosis Patients.

Authors:  Saam Noroozi; Hossein Ali Ebrahimi Meimand; Mohammad Kazemi Arababadi; Nouzar Nakhaee; Gholamreza Asadikaram
Journal:  Mol Neurobiol       Date:  2016-03-31       Impact factor: 5.590

5.  Cellular sources of dysregulated cytokines in relapsing-remitting multiple sclerosis.

Authors:  Jeppe Romme Christensen; Lars Börnsen; Dan Hesse; Martin Krakauer; Per Soelberg Sørensen; Helle Bach Søndergaard; Finn Sellebjerg
Journal:  J Neuroinflammation       Date:  2012-09-14       Impact factor: 8.322

Review 6.  Immune Components of Liver Damage Associated with Connective Tissue Diseases.

Authors:  Aziz A Chentoufi; Youri A Serov; Mansour Alazmi; Kamaldeen Baba
Journal:  J Clin Transl Hepatol       Date:  2014-03-15

Review 7.  The Meaning of Immune Reconstitution after Alemtuzumab Therapy in Multiple Sclerosis.

Authors:  Simona Rolla; Alessandro Maglione; Stefania Federica De Mercanti; Marinella Clerico
Journal:  Cells       Date:  2020-06-03       Impact factor: 6.600

8.  Long-Term Effects of Alemtuzumab on CD4+ Lymphocytes in Multiple Sclerosis Patients: A 72-Month Follow-Up.

Authors:  Simona Rolla; Stefania Federica De Mercanti; Valentina Bardina; Alessandro Maglione; Daniela Taverna; Francesco Novelli; Eleonora Cocco; Anton Vladic; Mario Habek; Ivan Adamec; Pietro Osvaldo Luigi Annovazzi; Dana Horakova; Marinella Clerico
Journal:  Front Immunol       Date:  2022-02-28       Impact factor: 7.561

9.  Switching and escalating therapy in long-lasting multiple sclerosis: not always necessary.

Authors:  Ana Teresa Carvalho; Maria José Sá
Journal:  ISRN Neurol       Date:  2012-12-22

10.  Alemtuzumab long-term immunologic effect: Treg suppressor function increases up to 24 months.

Authors:  Stefania De Mercanti; Simona Rolla; Angele Cucci; Valentina Bardina; Eleonora Cocco; Anton Vladic; Silva Soldo-Butkovic; Mario Habek; Ivan Adamec; Dana Horakova; Pietro Annovazzi; Francesco Novelli; Luca Durelli; Marinella Clerico
Journal:  Neurol Neuroimmunol Neuroinflamm       Date:  2016-01-21
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.